Trethera is a clinical-stage biopharmaceutical company focused on precise targeting of nucleotide metabolism for the treatment of cancers and autoimmune diseases. Led by an experienced drug development team and founded by recognized UCLA faculty, Trethera has developed TRE-515, a first-in-class inhibitor of deoxycytidine kinase (dCK) with potential applications in treating autoimmune diseases and cancers. The company aims to develop safer, more affordable, and efficacious treatments by targeting multiple pathways using rationally-designed combinations of drugs to improve efficacy and overcome limitations of previous single agent therapies.